The stock of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) is a huge mover today! About 1.27M shares traded hands. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) has declined 15.69% since April 13, 2016 and is downtrending. It has underperformed by 19.62% the S&P500.
The move comes after 6 months positive chart setup for the $1.01 billion company. It was reported on Nov, 15 by Barchart.com. We have $11.71 PT which if reached, will make NASDAQ:ZIOP worth $626.20M more.
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) Ratings Coverage
Out of 3 analysts covering Ziopharm Oncology (NASDAQ:ZIOP), 0 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 0 are positive. Ziopharm Oncology has been the topic of 5 analyst reports since December 4, 2015 according to StockzIntelligence Inc. The firm has “Underperform” rating by Wells Fargo given on Friday, December 4. Mizuho maintained ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) rating on Wednesday, May 11. Mizuho has “Neutral” rating and $7 price target. The rating was upgraded by Wells Fargo on Wednesday, August 10 to “Market Perform”. The rating was initiated by Raymond James with “Market Perform” on Thursday, June 2. The rating was maintained by Mizuho on Monday, January 25 with “Neutral”.
According to Zacks Investment Research, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment.”
Another recent and important ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) news was published by Fool.com which published an article titled: “Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics” on November 03, 2016.
ZIOP Company Profile
ZIOPHARM Oncology, Inc., incorporated on May 16, 2005, is a biopharmaceutical company. The Firm is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. The Company’s clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex. The Company’s Ad-RTS-IL-12 + veledimex uses gene delivery system to produce interleukin-12 (IL-12), a potent, naturally occurring anti-cancer protein. The Company’s initial drug candidate being developed using the synthetic immuno-oncology platform is Ad-RTS-IL-12 + veledimex.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.